Atacicpet, Sibeprenlimab Halt Decline in Kidney Function in IgA Nephropathy
9 Articles
9 Articles
Atacicpet, Sibeprenlimab Halt Decline in Kidney Function in IgA Nephropathy
(MedPage Today) -- DENVER -- Two IgA nephropathy drugs -- atacicept (Trutakna) and sibeprenlimab injection (Voyxact) -- showed they were able to slow kidney function decline in final phase III trial efficacy analyses. Atacicept and sibeprenlimab...
Otsuka’s Phase 3 VISIONARY Study Suggests Voyxact May Alter Disease Course in IgA Nephropathy
Final two-year data from the Phase 3 VISIONARY trial indicate that Voyxact (sibeprenlimab-szsi) may significantly slow progression of primary immunoglobulin A nephropathy (IgAN), preserving kidney function and reducing the likelihood of kidney failure events in patients at high risk of disease progression. A recent report by Otsuka, the findings of which were presented at ASN […]
Giornale Radio
Otsuka Pharmaceutical announced the final results at 2 years (24 months) of the Visionary Phase 3 study, which demonstrate prolonged preservation of renal function with sibeprenlimab in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. Sibeprenlimab treatment - reports a company note - stabilised renal function and decreased by 97.1% compared to placebo the risk of a composite renal outcome defined by the oc…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
